Closed-Loop Neurostimulation for Biomarker-Driven, Personalized Treatment of Major Depressive Disorder

Kristin K. Sellers; Ankit N. Khambhati; Noah Stapper; Joline M. Fan; Vikram R. Rao; Katherine W. Scangos; Edward F. Chang; Andrew D. Krystal

doi:10.3791/65177

Journal

/

Neuroscience

/

Closed-Loop Neurostimulation for Biomarker-Driven, Personalized Treatment of Major Depressive Disorder

JoVE Journal
Neuroscience

A subscription to JoVE is required to view this content. Sign in or start your free trial.

JoVE Journal Neuroscience

Closed-Loop Neurostimulation for Biomarker-Driven, Personalized Treatment of Major Depressive Disorder

2,237 Views

•

05:19 min

•

July 07, 2023

DOI:

10.3791/65177-v

DOI:

10.3791/65177-v

•

05:19 min

July 07, 2023

•

2192 Views

Kristin K. Sellers^1,2, Ankit N. Khambhati^1,2, Noah Stapper^2,3, Joline M. Fan^2,4, Vikram R. Rao^2,4, Katherine W. Scangos^2,3, Edward F. Chang^1,2, Andrew D. Krystal^2,3

¹Department of Neurological Surgery,University of California, San Francisco ²Weill Institute for Neurosciences,University of California, San Francisco ³Department of Psychiatry and Behavioral Sciences,University of California, San Francisco ⁴Department of Neurology,University of California, San Francisco

Summary

Deep brain stimulation triggered by a patient-specific neural biomarker of a high-symptom state may better control symptoms of major depressive disorder compared to continuous, open-loop stimulation. This protocol provides a workflow for identifying a patient-specific neural biomarker and controlling the delivery of therapeutic stimulation based on the identified biomarker.